CA2720851A1 - Oral pharmaceutical compositions in a molecular solid dispersion - Google Patents

Oral pharmaceutical compositions in a molecular solid dispersion Download PDF

Info

Publication number
CA2720851A1
CA2720851A1 CA2720851A CA2720851A CA2720851A1 CA 2720851 A1 CA2720851 A1 CA 2720851A1 CA 2720851 A CA2720851 A CA 2720851A CA 2720851 A CA2720851 A CA 2720851A CA 2720851 A1 CA2720851 A1 CA 2720851A1
Authority
CA
Canada
Prior art keywords
posaconazole
hpmcas
composition
molecular solid
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2720851A
Other languages
English (en)
French (fr)
Inventor
Larry Yun Fang
David Harris
Jiansheng Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2720851A1 publication Critical patent/CA2720851A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2720851A 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a molecular solid dispersion Abandoned CA2720851A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045,177 2008-04-15
PCT/US2009/040653 WO2009129301A2 (en) 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a molecular solid dispersion

Publications (1)

Publication Number Publication Date
CA2720851A1 true CA2720851A1 (en) 2009-10-22

Family

ID=41165581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720851A Abandoned CA2720851A1 (en) 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a molecular solid dispersion

Country Status (6)

Country Link
US (1) US20110034478A1 (cg-RX-API-DMAC7.html)
EP (1) EP2278957A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011516613A (cg-RX-API-DMAC7.html)
AU (1) AU2009236290A1 (cg-RX-API-DMAC7.html)
CA (1) CA2720851A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009129301A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129300A2 (en) * 2008-04-15 2009-10-22 Schering Corporation High density compositions containing posaconazole and formulations comprising the same
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN105283203B (zh) 2013-06-03 2018-12-28 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
PL3221308T3 (pl) 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
US11058682B2 (en) * 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP3925601B1 (en) 2016-02-26 2024-07-17 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) * 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN115038723A (zh) 2019-11-18 2022-09-09 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
EP4196096A1 (en) 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
WO2023012378A1 (en) 2021-11-25 2023-02-09 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN117545470A (zh) * 2023-09-18 2024-02-09 北京德立福瑞医药科技有限公司 泊沙康唑固体分散体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
US5790957A (en) * 1995-09-12 1998-08-04 Nokia Mobile Phones Ltd. Speech recall in cellular telephone
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
NZ507760A (en) * 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
PL212985B1 (pl) * 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2009129300A2 (en) * 2008-04-15 2009-10-22 Schering Corporation High density compositions containing posaconazole and formulations comprising the same

Also Published As

Publication number Publication date
WO2009129301A3 (en) 2009-12-23
US20110034478A1 (en) 2011-02-10
EP2278957A2 (en) 2011-02-02
WO2009129301A2 (en) 2009-10-22
AU2009236290A1 (en) 2009-10-22
JP2011516613A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
US20110034478A1 (en) Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs
JP7627302B2 (ja) パルボシクリブの固形剤形
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
CA2916143A1 (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
EP2323631A1 (en) Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
EP4037659B1 (en) Pharmaceutical composition comprising enzalutamide
US20150064252A1 (en) Solid dispersion formulation of an antiviral compound
CN114126712A (zh) 无定形司巴森坦(sparsentan)组合物
JP5635491B2 (ja) 固形医薬組成物
WO2009129297A1 (en) Semi-solid oral pharmaceutical compositions
JP7428356B2 (ja) 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用
WO2002067904A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
CN116437902A (zh) 包含美洛昔康的医药组成物
WO2024095137A1 (en) Pharmaceutical composition of empagliflozin and process thereof
US20100317642A1 (en) Pharmaceutical composition of orlistat
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
US12465565B2 (en) Pharmaceutical compositions of raltegravir
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin
WO2026019401A1 (en) A nanosuspension composition comprising canagliflozin
WO2025144121A1 (en) Empagliflozin composition with independent dissolution profile
EP4661846A1 (en) Milvexian pharmaceutical compositions
WO2024261701A1 (en) Edoxaban formulation.
WO2023080854A1 (en) Lurasidone hydrochloride compositions
EP4251162A1 (en) Improved manufacturing method for the formulations comprising vortioxetine hbr butanol solvate form h

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20150415